Search results
Key Points. This study found that the overall risk of breast cancer among hormonal contraceptive users is low. Because of the low baseline risks in the age groups using hormonal contraception (ie, premenopausal women), the risk difference between hormonal contraception users and nonusers is small.
23 wrz 2022 · Overall, 54.2% of patients reported contraceptive use at the time of breast cancer diagnosis, but a significant decrease in use was observed during primary treatment (year 1) and follow-up (year 2).
2 paź 2024 · Is hormonal contraception use associated with the risk of breast cancer (BC) for women with germline mutations in BRCA1 and BRCA2? Knowledge Generated. Hormonal contraceptive use in BRCA1 mutation carriers was associated with increased risk of BC, with users having a proportional increase in risk of 3% for each year of hormonal contraceptive use.
5 dni temu · A new study has found a link between hormonal intrauterine devices (IUDs) and breast cancer. But media reports of a large increase in risk may cause unnecessary worry.
7 gru 2017 · Nationwide registries provided individually updated information about the use of hormonal contraception, breast-cancer diagnoses, and potential confounders.
Current evidence suggests that LNG-IUS users have an increased breast cancer risk regardless of age and indication. The effect of LNG-IUS on breast cancer risk seems to be larger in older users. However, our systematic review detected methodological issues across the available studies, and confoundi …
8 mar 2022 · Levonorgestrel intrauterine sustained release system (LNG-IUS) is an intrauterine hormonal contraceptive device. Breast cancer (BC) was the most common type of cancer in women in the world in 2020. The relationship between LNG-IUS and BC is controversial.
